Geron Management to Present at Goldman Sachs Healthcare Conference
Event summary
- Geron management to participate in fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
- Live and archived audio webcast available via Geron’s Investors & Media section.
- Geron’s RYTELO® (imetelstat) approved in the U.S. and EU for lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
- Pivotal Phase 3 clinical trial ongoing for imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis.
The big picture
Geron’s participation in the Goldman Sachs Healthcare Conference underscores its focus on investor engagement amid critical clinical milestones. The company’s telomerase inhibitor, RYTELO, represents a key asset in the blood cancer space, with ongoing trials potentially expanding its market reach. The broader biopharmaceutical sector is watching closely as Geron navigates regulatory and competitive challenges in hematologic malignancies.
What we're watching
- Clinical Progress
- The pace at which Geron advances its Phase 3 trial for imetelstat in myelofibrosis will determine its near-term valuation.
- Regulatory Dynamics
- Whether Geron can sustain its regulatory approvals and expand indications for RYTELO in other hematologic malignancies.
- Market Positioning
- How Geron’s strategic positioning in blood cancer treatments will evolve amid competitive pressures and emerging therapies.
Related topics